Also, in epithelial carcinoma, activation of TGF-β pathway can inhibit carcinogenesis but promote metastasis [29, 30], this paradox has made the clinical use of TGF-β-pathway-related drugs highly debatable. This evidence concerns the gene TGFB1 and carcinoma.